In our previous studies, 150 or 75 U/kg (3 times/week, s.c.)of EPO were injected in rat models of type 1 diabetes mellitus, hypertension, and chronic kidney disease, and these doses of EPO did not affect hematocrit levels [7,8,9,10,11]. This evidence concerns the gene EPO and chronic kidney disease.